The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Tackling ischaemic heart disease in rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is the commonest form of chronic inflammatory arthritis. It causes significant disability and the efforts of the scientific community have concentrated on controlling symptoms, decelerating joint damage and improving function. However, it has been known for 50 yr [1] that RA is also associated with increased mortality [2, 3]. For severe RA, this compares to that of major killers such as triple‐vessel coronary heart disease (CHD) and some lymphomas [4, 5]. Despite advances in treatment, the mortality of RA does not appear to have changed over the last three decades [6, 7]. Its control, therefore, merits at least as much attention as the reduction of disability. An obvious target is reduction of cardiovascular mortality, which accounts for almost half of all deaths in RA [2, 3, 8]. In this article we describe the nature and significance of the problem, discuss the evidence for the involvement of atherosclerotic CHD, outline the role of classical and some novel cardiovascular risk factors, introduce potential lines for intervention, and provide a literature base for the interested reader. With the exception of a few studies [9–13], most epidemiological work suggests that cardiovascular mortality is increased in RA, with standardized mortality ratios of between 1.13 and 5.15 [14–25]. This very wide range may reflect variable susceptibility of the populations studied (e.g. geographic, genetic and dietary differences), different management practices [for both RA and cardiovascular disease (CVD)] or dissimilar study designs (e.g. inception vs established disease cohorts) [7]. There are only two possible explanations for excessive cardiovascular deaths in RA: CVD is either more prevalent or more deadly in RA patients than in general population counterparts. CVD collectively accounts for much of the comorbidity of RA [26, 27]. Rheumatoid heart disease, although common on echocardiography or autopsy, rarely has haemodynamic consequences; it is therefore an unlikely cause for the increased cardiovascular mortality of RA [28]. Instead, evidence is mounting that the main cause of cardiovascular death in RA is ischaemic heart disease (IHD). This is supported by studies showing that the incidence and/or prevalence of ischaemic cardiac pathologies, such as myocardial infarction (MI), congestive heart failure (CHF) and coronary death, are increased in RA compared with controls [18, 20, 22, 29, 30]. Using myocardial perfusion SPECT (single photon emission computed tomography) scans under pharmacological stress, we have shown that the prevalence of stable IHD in RA (50%) is twice that in closely matched osteoarthritic controls (27%). RA was an independent predictor of IHD in the total population studied [31]. Half of the RA patients with confirmed IHD had clinically silent disease, which has also been noted using 24‐h Holter monitoring [32]. In a separate study we found that a fifth of RA patients who sustained an acute coronary syndrome (ACS: unstable angina, Q‐wave or non‐Q‐wave MI) did not have chest pain on presentation, compared with none of the controls. Recurrent ACS was more common, occurred earlier and was associated with more deaths in these RA patients than in case‐matched controls [33]. There is therefore sufficient evidence to suggest that the major cause of increased cardiovascular death in RA is IHD rather than other cardiac pathologies, and that IHD is both more common and more likely to lead to death in RA than in the general population. Interestingly, this general picture is reminiscent of type‐2 diabetes mellitus (DM). Excessive cardiovascular morbidity (including silent IHD) and mortality in type‐2 DM are of similar magnitude to those now emerging for RA. Like DM, RA appears to be an independent risk factor for the development of IHD. The prevalence of the two conditions is not dissimilar, particularly in the 45 to 75+ age groups (RA vs DM: females, 1.67–2.99% vs 1.0–2.9%; males, 0.58–2.18% vs 1.6–4.6%) [31, 34–39; D. Symmons, personal communication]. In the context of the prevention, diagnosis, therapy and socioeconomic consequences of IHD, RA may be of similar importance to type‐2 DM. In the general population, the commonest cause of IHD is atherosclerotic CHD. The higher frequencies of stable IHD, first and recurrent ACS, and related deaths in RA could all be explained on the basis of accelerated formation and increased instability of coronary atherosclerotic plaques, compared with the general population. There is currently very little direct evidence for this. Most work has concentrated on the intima‐media thickness (IMT) of the carotid arteries. In the general population, IMT is a marker of early atherosclerosis and subsequent vascular events. Studies in RA suggest that IMT is increased compared with controls, indicating accelerated carotid atherosclerosis [40]. There are no comparative studies of the nature and extent of involvement of the coronary vasculature and the charac
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Statins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383
Perturbation of the T-cell repertoire in patients with unstable angina.
Liuzzo, G., Kopecky, S. L., Frye, R. L., Fallon, W. M. O., Maseri, A., Goronzy, J. J., & Weyand, C. M. (1999) · Circulation · doi:10.1161/01.cir.100.21.2135 · Cited by 398
Petri, M., Lakatta, C., Magder, L., & Goldman, D. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90151-1 · Cited by 323
Cited by
The Endothelium and Its Role in Regulating Vascular Tone
Sandoo, A., Veldhuijzen van Zanten, J. J. C. S., Metsios, G. S., Carroll, D., & Kitas, G. D. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010302 · Cited by 814
Self-citationWriting a narrative biomedical review: considerations for authors, peer reviewers, and editors
Gasparyan, A. Y., Ayvazyan, L., Blackmore, H., & Kitas, G. D. (2011) · Rheumatology International · doi:10.1007/s00296-011-1999-3 · Cited by 694
Self-citationvan Halm, V. P., Peters, M. J. L., Voskuyl, A. E., Boers, M., Lems, W. F., Visser, M., Stehouwer, C. D. A., Spijkerman, A. M. W., Dekker, J. M., Nijpels, G., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094151 · Cited by 359
Young, A., Koduri, G., Batley, M., Kulinskaya, E., Gough, A., Norton, S., Dixey, J., & on behalf of the Early Rheumatoid Arthritis Study (ERAS) group (2006) · Rheumatology · doi:10.1093/rheumatology/kel253 · Cited by 354
Cardiovascular morbidity in psoriatic arthritis
Gladman, D. D., Ang, M., Su, L., Tom, B. D. M., Schentag, C. T., & Farewell, V. T. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094839 · Cited by 304
Metadata
- Authors
- Kitas, G. D.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03-31
- Volume
- 42
- Issue
- 5
- Pages
- 607-613
- ISSN
- 0263-7103 (ISSN-L)
- 1460-2172
- OpenAlex
- W2166396149
- Cited by
- 180
- References
- 11
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tackling ischaemic heart disease in rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/keg175
- The paper
- Kitas, G. D. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/keg175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.